

Atty. Docket No.

Serial No.

JC20-368

10/539451

INFORMATION DISCLOSURE
CITATION

Applicant

STEVENS et al.

Filing Date

TC/A.U.

(Use several sheets if necessary)

June 20, 2005

unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5,391,570 A	02/1995	CATT et al.				
	6,153,611	11/2000	Mattson et al.				

FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
03 004479 A	01/2003	WO				
0 469 984 A	02/1992	EP				
WO 01/92239	12/2001	WO				
EP 0 546 583	12/1992	EP				

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE
CITATION

Atty. Docket No.

Serial No.

120-368

10/539451

Applicant

unl. wh

STEVENS et al.

Filing Date

TC/A.U.

June 20, 2005

unknown

(Use several sheets if necessary)

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	International Search Report of PCT/GB02/05842, mailed April 2, 2003
	Alcaraz, L., et al., 1998, "Manumycin A: synthesis of the (+)-enantiomer and revision of stereochemical assignment," <i>J. Org. Chem.</i> , Vol. 63, pp. 3526-3527.
	Alley et al., 1988, "Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay," <i>Cancer Research</i> , Vol. 48, p. 589.
	Boyd, M.R., Paull, K.D., 1995, "Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery system," <i>Drug Dev. Res.</i> , Vol. 34, pp. 91-104.
	Callinan et al., 1990, "Spiro-annulated 2,5-cyclohexadienones via oxidation of 2'-alkenyl-p-phenyl phenols with iodobenzene diacetate," <i>Tetrahedron Letters</i> , Vol. 31, No. 32, pp. 4551-4552.
	Capparelli et al., 1987, "Structural and solvent/electrolyte effects on the selectivity and efficiency of the anodic oxidation of para-substituted aromatic ethers. An efficient route to quinol ether ketals and quinol ethers," <i>J. Org. Chem.</i> , Vol. 52, pp 4953-4961.
	Collins, L.; Franzblau, S.G.; 1997, "Microplate Alamar Blue Assay versus BACTEC 460 System for High-throughput Screening of Compounds against <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium avium</i> ," <i>Antimicrob. Agents Chemother.</i> , Vol. 41, pp. 1004-1009.
	Dengler et al., 1995, "Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays," <i>Anti-cancer drugs</i> , Vol. 6, pp. 522-532.
	Dodge, J.A., et al., 1988, "Competitive dienone-phenol type rearrangements for the regioselective preparation of 2,4-disubstituted-naphth-1-ols," <i>Tetrahedron Letters</i> , Vol. 29, No. 38, p. 4827-4830.
	Faaland et al., 1991, "Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF) stimulated EFG receptor tyrosine kinase activity," <i>Mol. Cell Biol.</i> , Vol. 11, pp. 2697-2703.
	Gasdaska et al., 1994, "The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived cofactor (ADF): thioredoxin mRNA is elevated in some human tumors," <i>Biochimica et Biophysica Acta</i> , Vol. 1218, p. 292.
	Geran et al., 1972, "Protocols for screening chemical agents and natural products against tumor and other biological systems," <i>Cancer Chemother. Rep.</i> , Vol. 3, p. 1-103.
	Hutchinson et al., 2001, Antitumour benzothiazoles. 14. Synthesis and in vitro biological properties of fluoroinated 2-(4-aminophenyl)benzothiazoles," <i>J. Med. Chem.</i> , Vol. 44, pp. 1446-1455.
	Kirkpatrick et al., 1999, "Parallel synthesis of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents," <i>Anti-Cancer Drug Design</i> , Vol. 14, pp. 421-432.
	Kunkel et al., 1997, "Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs," <i>Anti-Cancer Drug Design</i> , Vol. 12, pp. 659-670.
	McKillip et al., 1993, "A concise synthesis of the novel antibiotic aranorosin," <i>Tetrahedron Lett.</i> , Vol. 34, pp. 5519-5522.
	Milić, D. R., et al., "X-Ray crystal structure of 10β-hydroxy-4β,5β-epoxyestr-1-en-3,17-dione and antitumor activity of its congeners," <i>Molecules</i> , Vol. 4, pp. 338-352.
	Oblong et al., 1993, "Purification of human thioreductase; properties and characterization by absorption and circular dichroism spectroscopy," <i>Biochemistry</i> , Vol. 32, p. 7271.
	Pelter, A., Elgendi, S.M.A., 1993, "Phenolic oxidations with phenyliodonium diacetate," <i>J. Chem. Soc., Perkin Trans. 1</i> , pp. 1891-1896.
	Powis, G., Mustacich, D, Coon, A., 2000, "The role of the redox protein thioredoxin in cell growth and cancer," <i>Free Radical Biology & Medicine</i> , Vol. 29, Nos. 3/4, pp. 312-322.
	Ramdas et al., 1994, "The degree of inhibition of protein tyrosine kinase activity by Tyrphostin 23 and 25 is related to their instability," <i>Cancer Research</i> , Vol 54, pp. 867-869.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Afty. Docket No.

Serial No.

10/539451

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

STEVENS et al.

Filing Date

TC/A.U.

June 20, 2005

unknown

*Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.